FCAAIA Notes: Twenty years ago the SMART study suggested a risk of long-acting beta agonists (LABA) use, However, the rail was associated with the use of LABA alone and NOT with the concurrent use of inhaled corticosteroids (ICS). Study after study shows that when used in combination with ICS, LABAs do not increase risk of asthma morbidity or mortality. Of course, the patients who need LABAs along with their ICS have more severe asthma to start with, so their risk is greater than those who do not require LABAs.
An important point is that many patients who use ICS/LABA combinations have never tried and ICS alone. Continue reading “REVISITING THE SAFETY OF LABAS IN CHILDREN WITH SEVERE ASTHMA”
FCAAIA Notes: No medication can give its best benefit if not taken properly. The same holds true for metered dose inhalers for asthma. If your inhaler does not help when you use it, maybe your technique is a little off.
Correct inhaler technique is difficult. There are a few small and simple steps like remembering to shake the inhaler before use. Other steps are harder. When the canister is depressed, the medication comes out at 60-80 mph. No wonder it is tough to coordinate the puff and the inhalation! As demonstrated in this article, errors are more than just common; they are practically the norm.
Do you need a review? Continue reading “APPROPRIATE USE OF PRESSURIZED METERED-DOSE INHALERS FOR ASTHMA”
FCAAIA Notes: The long-acting Beta 2-agonists are long-acting cousins of albuterol. They are found in such combination medications as Advair, Symbicort, and Dulera. These medications are very useful; and are required for many patients with asthma. However, they are not indicated for EVERY patient with asthma or for “as needed” symptom relief. Patients should have their inhaled steroid dose optimized. In addition, many patients requiring the combination medications can later be “stepped down” to the inhaled steroid alone. Continue reading “CONTROVERSIES REGARDING LONG-ACTING BETA 2-AGONISTS”